GAMMA Investing LLC Increases Position in BioNTech SE (NASDAQ:BNTX)

GAMMA Investing LLC increased its stake in BioNTech SE (NASDAQ:BNTX - Free Report) by 5,710.8% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 53,634 shares of the company's stock after purchasing an additional 52,711 shares during the quarter. GAMMA Investing LLC's holdings in BioNTech were worth $4,884,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Jones Financial Companies Lllp boosted its holdings in BioNTech by 110.3% during the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock valued at $53,000 after acquiring an additional 246 shares during the period. Quintet Private Bank Europe S.A. boosted its stake in BioNTech by 823.5% during the 4th quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company's stock valued at $88,000 after purchasing an additional 700 shares during the last quarter. Allianz SE bought a new position in shares of BioNTech during the 4th quarter valued at $90,000. Generali Investments CEE investicni spolecnost a.s. bought a new position in shares of BioNTech during the 4th quarter valued at $137,000. Finally, AlphaCentric Advisors LLC bought a new position in shares of BioNTech during the 4th quarter valued at $168,000. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

BioNTech Stock Up 1.6%

NASDAQ BNTX traded up $1.65 on Friday, hitting $106.57. The stock had a trading volume of 1,328,302 shares, compared to its average volume of 950,742. The business's fifty day moving average price is $100.98 and its 200 day moving average price is $108.15. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. BioNTech SE has a 52-week low of $76.53 and a 52-week high of $131.49. The stock has a market cap of $25.62 billion, a price-to-earnings ratio of -50.75 and a beta of 1.29.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Citigroup reaffirmed a "buy" rating and issued a $140.00 target price (down from $145.00) on shares of BioNTech in a report on Tuesday, May 6th. Truist Financial restated a "buy" rating and set a $155.00 price objective (up previously from $151.00) on shares of BioNTech in a research report on Tuesday, June 3rd. Wall Street Zen upgraded BioNTech from a "sell" rating to a "hold" rating in a research report on Saturday, June 7th. The Goldman Sachs Group began coverage on BioNTech in a research report on Thursday, May 29th. They issued a "neutral" rating and a $110.00 price target for the company. Finally, Leerink Partners set a $112.00 price target on BioNTech in a research report on Monday, June 2nd. Five analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $138.25.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.